

## DAFTAR PUSTAKA

- Adami, H.O., Lambe, M., Persson, I., Ekblom, A., Hsieh, C.C., Trichopoulos, D., Leon, D. and Janson, P.O., (1994). 'Parity, age at first childbirth, and risk of ovarian cancer'. *The Lancet*, 344(8932), pp.1250-1254.
- Ahyar, I., Rachman, I. T. and Kusumanto, A. (2017) 'Regimen Paclitaxel dan Carboplatin dengan Regimen Cyclophosphamide, Adriamycin dan Cisplatin', *Jurnal Kesehatan Reproduksi*, 4(1), pp. 1–10.
- Akin, J. M. and Waddell, J. A. (2014) 'Paclitaxel and Carboplatin (TC) Regimen for Ovarian Cancer', *Hosp Pharm*, 49(5), pp. 425–431. doi: 10.1310/hpj4905-425.
- Aravantinos, G., Fountzilas, G., Bamias, A., Grimani, I., Rizos, S., Kalofonos, H.P., Skarlos, D.V., Economopoulos, T., Kosmidis, P.A., Stathopoulos, G.P. and Briasoulis, E., 2008 'Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. *European Journal of Cancer*, 44(15), pp.2169-2177.
- Tortorella, L., Vizzielli, G., Fusco, D., Cho, W. C., Bernabei, R., Scambia, G., & Colloca, G. (2017) 'Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments', 8(5), 677–684.
- Aluloski, I., Tanturovski, M., Jovanovic, R., Kostadinova-kunovska, S., & Petrushevska, G. (2017). Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia, 5(7), 904–908.
- American Cancer Society, A. C. S. (2018) *What is Ovarian Cancer ?*, American Cancer Society.
- American Institute for Cancer Research, W. C. R. F. (2018) 'Diet, Nutrition , Physical Activity and Ovarian Cancer', *Continuous Update Project*.
- Baldwin, L. A., Huang, B., Miller, R. W., Tucker, T., Goodrich, S. T., Podzielinski, I., Desimone, C. P. and Ueland, F. R. (2012) 'Ten-Year Relative Survival for Epithelial Ovarian Cancer', *Obstetrics & Gynecology*, 120(3), pp. 612–618.
- Baumann, K. H., Bois, A., Meier, W., Rau, J., Wimberger, P., Sehouli, J. and Kurzeder, C. (2012) 'A Phase II Trial (AGO 2.11) in Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Trial with Sunitinib (SU11248) to Evaluate Dosage, Schedule, Tolerability, Toxicity and Effectiveness of A Multitargeted Receptor Tyrosine Kinase Inhibitor Monother', *Annals of Oncology*, 23, pp. 2265–2271. doi: 10.1093/annonc/mds003.
- Berek, J. S. and Hillard, P. J. A. (2012) 'Initial Assessment and Communication', in *Berek and Novak's Gynecology*. 15th Ed. Lippincott Williams and

Wilkins.

- CA, D., AR, D. and AE, M. (2016) 'Diagnosis and Management of Ovarian Cancer', *Am Fam Physician*, 93(11), pp. 937–44.
- Chen, M., Jin, Y., Bi, Y., Yin, J., Wang, Y., & Pan, L. (2014). 'A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology'. *OncoTargets and therapy*, 7, 1891.
- Christina, I. M., Philipp, F., Hauptmann, S., Sehouli, J., Mucinous, E. Á. and Clear, Á. (2016) 'The New WHO classification of Ovarian, Fallopian tube , and Primary Peritoneal Cancer and Its Clinical Implications', *Archives of Gynecology and Obstetrics*. Springer Berlin Heidelberg, 293(4), pp. 695–700. doi: 10.1007/s00404-016-4035-8.
- Coleman, R. L., Monk, B. J., Sood, A. K. and Herzog, T. J. (2013) 'Latest Research and Treatment of Advanced-Stage Epithelial Ovarian Cancer', *Nature Reviews : Clinical Oncology*. Macmillan, 10(4), pp. 211–224. doi: 10.1038/nrclinonc.2013.5.
- Colombo, N., Peiretti, M., Parma, G., Lapresa, M., Mancari, R., Carinelli, S., Sessa, C. and Castiglione, M. (2010) 'Clinical Practice Guidelines Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma : ESMO Clinical Practice Guidelines for Diagnosis , Treatment and Follow-up Clinical Practice Guidelines', *Annals of Oncology*, 21(Supplement 5), pp. 23–30. doi: 10.1093/annonc/mdq244.
- de Boo, L.W., Vulink, A.J.E. and Bos, M.E.M.M. (2017). 'Metronomic cyclophosphamide-induced long-term remission after recurrent high-grade serous ovarian cancer: A case study'. *Molecular and clinical oncology*, 7(6), pp.1130-1134.
- Deng, F., Xu, X., Lv, M., Ren, B., Wang, Y., Guo, W., Feng, J. and Chen, X. (2017) 'Age is Associated with Prognosis in Serous Ovarian Carcinoma', *Journal of Ovarian Research*. Journal of Ovarian Research, 10, p. 36. doi: 10.1186/s13048-017-0331-6.
- Devita, V. T., Rosenberg, S. A., Paget, S. and Avery, O. (2012) 'Two Hundred Years of Cancer Research', *the New England Journal of Medicine*, pp. 2207–2214.
- Ezzati, M., Abdullah, A., Shariftabrizi, A., Hou, J., Kopf, M., Stedman, J. K., Samuelson, R. and Shahabi, S. (2014) 'Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma', *International Scholarly Research Notices*. Hindawi Publishing Corporation, (953509). doi: 10.1155/2014/953509.
- Feng, Y. H. (2015). 'The association between obesity and gynecological cancer'. *Gynecology and Minimally Invasive Therapy*, 4(4), 102-105.
- Ferrandina, G., Corrado, G., Mascilini, F., Malaguti, P., Samaritani, R., Distefano,

- M., Masciullo, V., Di Legge, A., Savarese, A. and Scambia, G. (2014). 'Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study'. *BMC cancer*, 14(1), p.947.
- Gaitskell, K., Green, J., Pirie, K., Reeves, G., & Beral, V. (2014). OP26 Parity and ovarian cancer in the Million Women Study: variation by histological subtype.
- Giannopoulos, T., Butler-Manuel, S., Taylor, A., Ngeh, N. and Thomas, H. (2006) 'Clinical Outcomes of Neoadjuvant Chemotherapy and Primary Debulking Surgery in Advanced Ovarian Carcinoma.', *European Journal of Gynaecological Oncology*, 27(1), pp. 25–28.
- Gupta, D. and Lis, C. G. (2009) 'Role of CA125 in Predicting Ovarian Cancer Survival - A Review of the Epidemiological Literature', *Journal of Ovarian Research*, 2(13), pp. 1–20. doi: 10.1186/1757-2215-2-13.
- Hoffman, B. L., Schorge, J. O., Schaffer, J. I., Halvorson, L. M., Bradshaw, K. D. and Cunningham, F. G. (2012) *William Gynecology*. 2nd editio. Mc Graw Hill.
- Jung, K., Kong, H., Oh, C. and Lee, D. H. (2015) 'Cancer Statistics in Korea : Incidence , Mortality , Survival , and Prevalence in 2012', *Cancer Res Treat*, 47(2), pp. 127–141.
- Kang, W. D., Choi, H. S. and Kim, S. M. (2010) 'Gynecologic Oncology Value of Serum CA125 Levels in Patients with High-Risk , Early Stage Epithelial Ovarian Cancer', *Gynecologic Oncology*. Elsevier Inc., 116(1), pp. 57–60. doi: 10.1016/j.ygyno.2009.09.019.
- Kementerian Kesehatan RI, P. D. dan I. (2015) 'Situasi Penyakit Kanker', *Infodatin*.
- Kurman, R. J., & Shih, I. M. (2010). 'The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory'. *The American journal of surgical pathology*, 34(3), 433.
- Kurnianda, J., Widayati, K., Purwanto, I., Hardianti, M. S. and Wulanningsih, W. (2011) *Buku Protokol Kemoterapi : Pedoman Tatalaksana Terapi Sistemik pada Kanker*.
- Liu, Z., Zhang, T. T., Zhao, J. J., Qi, S. F., Du, P., Liu, D. W., & Tian, Q. B. (2015). 'The association between overweight, obesity and ovarian cancer: a meta-analysis'. *Japanese journal of clinical oncology*, 45(12), 1107-1115.
- Matz, M., Coleman, M.P., Sant, M., Chirlaque, M.D., Visser, O., Gore, M., Allemani, C., Bouzbid, S., Hamdi-Chérif, M., Zaidi, Z. and Bah, E. (2017). 'The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-

- 2)'. *Gynecologic oncology*, 144(2), 405-413.
- Mok, S. C., Kwong, J., Welch, W. R., Samimi, G. and Ozbun, L. (2007) 'Etiology and Pathogenesis of Epithelial Ovarian Cancer', *Disease Markers*, 23, pp. 367-376.
- Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-gamez, J. N., Behbakht, K., Chen, L., Copeland, L., Crispens, M. A., Derosa, M., Dorigo, O., Gershenson, D. M., Gray, H. J., Hakam, A., Havrilesky, L. J., Johnston, C., Lele, S., Martin, L., Penson, R. T., Percac-lima, S., Pineda, M., Plaxe, S. C., Powell, M. A., Ratner, E., Remmenga, S. W., Rose, P. G., Sabbatini, P., Santoso, J. T., Werner, T. L. and Burns, J. (2016) 'Ovarian Cancer , Clinical Practice Guidelines in Oncology', *Journal of the National Comprehensive Cancer Network*, 14(9), pp. 1134-1163.
- National Cancer Institute, N. C. I. (2019) *Definition of Ovarian Cancer*, *National Cancer Institute*.
- Pacheca-Palomar, M.T., Montes A., Turner, J. (2010). 'Paclitaxel and Carboplatin in Advanced Ovarian , Fallopian Tube and Primary Peritoneal Cancer'. *South east london network NHS*, 23-25.
- Pradjatmo, H. (2016). 'Impact of preoperative serum levels of CA 125 on epithelial ovarian cancer survival'. *Asian Pac J Cancer Prev*, 17(4), 1881-1886.
- Reid, B. M., Permuth, J. B. and Sellers, T. A. (2017) 'Epidemiology of Ovarian Cancer : A Review Pathologic Classification of OC', *Cancer Biol Med*, pp. 9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.
- Ries, L. A. G. (1987) 'Ovarian Cancer Survival and Treatment Differences by Age', *Surveillance, Epidemiology and End Results (SEER) Program, National Cancer Institute, National Institutes of Health*, pp. 524-529.
- Romanidis, K., Nagorni, E. A., Halkia, E., & Pitiakoudis, M. (2014). 'The role of cytoreductive surgery in advanced ovarian cancer: the general surgeon's perspective'. *Management*, 7(9), 12.
- Salehi, F., Dunfield, L., Phillips, K. P., Krewski, D., Salehi, F., Dunfield, L., Phillips, K. P. and Krewski, D. (2008) 'Risk Factors for Ovarian Cancer : An Overview with Emphasis on Hormonal Factors', *Journal of Toxicology and Environmental Health, Part B*, 7404(11), pp. 301-321. doi: 10.1080/10937400701876095.
- Shapira, I., Oswald, M., Lovecchio, J., Khalili, H., Menzin, A., Whyte, J., Santos, L. Dos and Liang, S. (2013) 'Circulating Biomarkers for Detection of Ovarian Cancer and Predicting Cancer Outcomes', *British Journal of Cancer*. Nature Publishing Group, 110(4), pp. 976-983. doi: 10.1038/bjc.2013.795.
- Sihombing, M. and Sirait, A. M. (2007) 'Angka Ketahanan Hidup Penderita

Kanker Ovarium di RS Dr . Cipto Mangunkusumo Jakarta', *Majalah Kedokteran Indonesia*, 57(10), pp. 346–352.

The International Collaborative Ovarian Neoplasm (ICON) Group, T. I. C. O. N. (ICON) G. (2002) 'Paclitaxel Plus Carboplatin Versus Standard Chemotherapy with either Single-Agent Carboplatin or Cyclophosphamide, Doxorubicin, and Cisplatin in Women with Ovarian Cancer : the ICON3 Randomised Trial', *Lancet*, 360, pp. 505–515.

Tworoger, S. S., & Huang, T. (2016). 'Obesity and ovarian cancer'. In *Obesity and Cancer* (pp. 155-176). Springer, Cham.

Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A. and Kaye, S. B. (2004) 'Phase III Randomized Trial of Docetaxel – Carboplatin Versus Paclitaxel – Carboplatin as First-line Chemotherapy for Ovarian Carcinoma', *Journal of the National Cancer Institute*, 96(22). doi: 10.1093/jnci/djh323.

Widadgo, Ruly. and Pradjatmo, H. (2009) 'Angka harapan hidup penderita kanker ovarium Rumah Sakit Sardjito', *PhD Thesis Universitas Gadjah Mada*.

Yang, Z.J., Zhao, B.B. and Li, L. (2016) 'The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer'. *Journal of ovarian research*, 9(1), p.57.

Zeppernick, F. and Meinhold-Heerlein, I. (2014) 'The New FIGO Staging System for Ovarian, Fallopian Tube , and Primary Peritoneal Cancer', *Arch Gynecol Obstet*, 290, pp. 839–842. doi: 10.1007/s00404-014-3364-8.

Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M.N. and Rubin, S.C., (2003). 'Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer'. *New England journal of medicine*, 348(3), pp.203-213